Aura Biosciences (AURA) Capital Expenditures (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Capital Expenditures data on file, last reported at $46000.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $46000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $493000.0 (down 56.41% YoY) and the FY2025 annual result came in at $447000.0, down 64.33% from the prior year.
• Capital Expenditures eased to $46000.0 in Q1 2026, from $176000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q4 2024 to a low of -$556000.0 in Q4 2022.
• A 5-year average of $126250.0 and a median of $112000.0 in 2022 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 1135.12% in 2024, down 269.08% in 2024.
• Tracing AURA's Capital Expenditures over 5 years: stood at -$556000.0 in 2022, then jumped by 69.78% to -$168000.0 in 2023, then soared by 1135.12% to $1.7 million in 2024, then sank by 89.88% to $176000.0 in 2025, then sank by 73.86% to $46000.0 in 2026.
• The last three Capital Expenditures figures came in at $46000.0 (Q1 2026), $176000.0 (Q4 2025), and $45000.0 (Q3 2025), per Business Quant data.